6:05 PM · 16 July 2021

Zynex stock surges 7% as orders increased by 247%

Zynex Medical (ZYXI.US) stock surged more than 7% during today's session, extending yesterday's gains. A manufacturer of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics yesterday announced that the number of orders in the second quarter increased by 247% y /y. Zynex expects quarterly revenue in the range of $ 31.0 million - $ 32.5 million. Second quarter Adjusted EBITDA is now expected to come in between $4.2 and $5.2 million compared to the previous estimate of between $3.0 and $4.0 million. A full report on Q2 results will be presented at the end of July.

In the announcement, the company pointed to the development of NexWave technology, which is recommended to patients as one of the first solutions to reduce chronic and acute pain without any side effects. The company stressed that the device is a safe alternative to opioids such as morphine.

Zynex Medical (ZYXI.US) stock broke above the 50- and 100-session moving average. On the daily chart, it's worth noting that price remain with the broad wedge formation. Currently, stock is approaching the upper limit of this pattern. Source: xStation5

18 June 2026, 6:55 PM

Daily Summary: Dollar at 1-year high, stocks rebound on renewed risk appetite 🚀 (18.06.2026)

18 June 2026, 6:15 PM

Amazon Eyes External Sales of Custom AI Chips, Threatening Nvidia’s Dominance

18 June 2026, 4:11 PM

Stock of the Week: KLA Corporation and the Economics of Error in the Age of Artificial Intelligence

18 June 2026, 2:58 PM

US OPEN: Indices Recover Amid More Expensive iPhones and GTA 6 Preorders (18.06.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits